AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9057430 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day treatment with bismuth, metronidazole, and tetracycline
Number of subjects: 30
Study 8161424 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 143
Study 8161424 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 143
Study 2868657 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-treated group (Hydrochlorothiazide, propranolol, methyldopa)
Number of subjects: 785
Study 2868657 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 785
Study 2868657 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (short-term trial)
Number of subjects: 785
Study 30149775 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper impregnated compression stockings
Number of subjects: 16
Study 30149775 — intervention group
Group type: COMPARATOR
Intervention: Standard compression stockings (control)
Number of subjects: 16
Study 28740352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 50
Study 28740352 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-challenging foods after low FODMAP diet
Number of subjects: 50
Study 25442396 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based impregnated wipes
Number of subjects: 0
Study 25442396 — intervention group
Group type: COMPARATOR
Intervention: Quaternary ammonium-based impregnated wipes
Number of subjects: 0
Study 23849341 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 0
Study 23849341 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study 21718474 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g methylprednisolone for three consecutive days
Number of subjects: 266
Study 21718474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 18635341 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600mg intravenously every 12h
Number of subjects: 142
Study 18635341 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1g intravenously every 12h (for patients aged < or =60 years) or 0.75g (for patients aged >60 years)
Number of subjects: 142
Study 16507515 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 18
Study 16507515 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 18
Study 15452309 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 15452309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11506100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg cisatracurium
Number of subjects: 48
Study 11506100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg cisatracurium
Number of subjects: 48
Study 11506100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg cisatracurium
Number of subjects: 48
Study 9402568 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback group
Number of subjects: 20
Study 9402568 — intervention group
Group type: COMPARATOR
Intervention: No visual feedback group
Number of subjects: 20
Study 8291370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methyl prednisolone (HDMP) 10 mg/kg/day for 5 days i.v. (n = 10)
Number of subjects: 350
Study 8291370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days (n = 10)
Number of subjects: 350
Study 8291370 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose prednisone (CDP) 2 mg/kg/day for 4 weeks p.o. (n = 10)
Number of subjects: 350
Study 8291370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine 1.5 mg/m2/week i.v. 4 doses (n = 4)
Number of subjects: 350
Study 8291370 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 0.4 g/kg/day for 5 days (n = 8)
Number of subjects: 350
Study 8291370 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy (n = 12)
Number of subjects: 350
Study 2825856 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl‐salicylic acid as an anti‐aggregant agent
Number of subjects: 320
Study 2825856 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 320
Study 2825856 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic central nervous system irradiation
Number of subjects: 320
Study 31096162 — intervention group
Group type: EXPERIMENTAL
Intervention: ROS-responsive nanoparticles with light-triggered size-reducing, loaded with camptothecin (CPT)
Number of subjects: 0
Study 27487492 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 90
Study 27487492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 90
Study 27487492 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 90
Study 26060122 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prasugrel loading dose (LD) followed by an additional 30 mg prasugrel at the time of PCI
Number of subjects: 4033
Study 26060122 — intervention group
Group type: COMPARATOR
Intervention: Placebo LD followed by 60 mg prasugrel at the time of PCI
Number of subjects: 4033
Study 26060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with prasugrel LD
Number of subjects: 4033
Study 26060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral access
Number of subjects: 4033
Study 26060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 4033
Study 26060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of >1 stent
Number of subjects: 4033
Study 26060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4033
Study 26060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Performed PCI
Number of subjects: 4033
Study 26060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy with glycoprotein IIb/IIIa inhibitors
Number of subjects: 4033
Study 23434910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep following implicit training
Number of subjects: 0
Study 23434910 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sleep slow-wave activity
Number of subjects: 0
Study 23434910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger hippocampal activation at explicit knowledge retrieval
Number of subjects: 0
Study 23434910 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced reprocessing of hippocampal memory representations during slow-wave sleep
Number of subjects: 0
Study 21220480 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus tamoxifen
Number of subjects: 290
Study 21220480 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus tamoxifen
Number of subjects: 290
Study 19751326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental support device (DSD)
Number of subjects: 64
Study 19751326 — intervention group
Group type: COMPARATOR
Intervention: Non-device group
Number of subjects: 64
Study 19751326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 17181650 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3.0 mg/day
Number of subjects: 493
Study 17181650 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 493
Study 17181650 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3.0 mg/day with basiliximab
Number of subjects: 493
Study 17181650 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day with basiliximab
Number of subjects: 493
Study 17181650 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (both doses)
Number of subjects: 493
Study 15363071 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention ICD patients
Number of subjects: 978
Study 15363071 — intervention group
Group type: COMPARATOR
Intervention: Secondary prevention ICD patients
Number of subjects: 978
Study 11920260 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan 9 mg/m2 p.o. and prednisone 60 mg/m2 days 1-4)
Number of subjects: 914
Study 11920260 — intervention group
Group type: EXPERIMENTAL
Intervention: VCMP/VBAP 'SD' (vincristine 1 mg i.v. on day 1, cyclophosphamide 500 mg/m2 i.v. on day 1, melphalan 6 mg/m2 p.o. on days 1-4, and prednisone 60 mg/m2 on days 1-4)
Number of subjects: 914
Study 11920260 — intervention group
Group type: EXPERIMENTAL
Intervention: VCMP/VBAP 'HD' (increased doses of cyclophosphamide and doxorubicin)
Number of subjects: 914
Study 9682526 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass exposure (ME) group
Number of subjects: 31
Study 9682526 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanding-spaced exposure (ESE) group
Number of subjects: 31
Study 7920946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol valerate (E2-V) 4 mg/day for 28 days
Number of subjects: 71
Study 2911997 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation (10 mg/d)
Number of subjects: 51
Study 2911997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E supplementation (20 mg/kg/d)
Number of subjects: 51
Study 2911997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 51
Study 1095132 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole for two weeks
Number of subjects: 45
Study 1095132 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole for six months
Number of subjects: 45
Study 1095132 — intervention group
Group type: COMPARATOR
Intervention: Control group (dummy tablets)
Number of subjects: 45
Study 30732912 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 45
Study 30732912 — intervention group
Group type: COMPARATOR
Intervention: Control condition (lifestyle improvement)
Number of subjects: 45
Study 31628790 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance-Cerebrovascular Accident (GLB-CVA) intervention, a 12-month weight loss program modified for stroke patients.
Number of subjects: 64
Study 31628790 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group.
Number of subjects: 64
Study 28323947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-carotenoid supplementation (MCS)
Number of subjects: 20
Study 28323947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26377389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal balloon autoinflation performed three times per day for 1-3 months plus usual care
Number of subjects: 320
Study 26377389 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 320
Study 23811643 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser
Number of subjects: 30
Study 23811643 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064 nm Nd:YAG laser
Number of subjects: 30
Study 23811643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 30
Study 20177421 — intervention group
Group type: EXPERIMENTAL
Intervention: p38 kinase inhibitor
Number of subjects: 0
Study 20177421 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific enzyme inhibitors and expressed recombinant enzymes
Number of subjects: 0
Study 20177421 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation within Aox1
Number of subjects: 0
Study 19705093 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment (5 sessions over 8 weeks)
Number of subjects: 35
Study 19705093 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (training program with simple gymnastic and physiotherapeutic exercises)
Number of subjects: 35
Study 17044952 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 60
Study 17044952 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold electrical stimulation (TES)
Number of subjects: 60
Study 17044952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14578921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg once daily (titrated to 20 mg if required)
Number of subjects: 222
Study 14578921 — intervention group
Group type: COMPARATOR
Intervention: Lacidipine 2 mg once daily (titrated to 4 mg if required)
Number of subjects: 222
Study 10699342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing recombinant MSP2 (3D7 allele), MSP1 (190LCS.T3), and RESA antigen (C terminal 771 amino acids) in Montanide ISA 720 adjuvant, administered in two doses 6 weeks apart.
Number of subjects: 17
Study 10699342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjuvant emulsion), administered in two doses 6 weeks apart.
Number of subjects: 17
Study 10699342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (vaccine and placebo) were challenged with approximately 140 ring infected red cells of the 3D7 cloned line, 4 weeks after the second dose.
Number of subjects: 17
Study 10699342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine and placebo groups.
Number of subjects: 17
Study 9471828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser therapy (904 nm, 5 kHz, in the dose of 1 J/cm2)
Number of subjects: 32
Study 9471828 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid infiltration
Number of subjects: 32
Study 9471828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of corticosteroid infiltration and laser therapy
Number of subjects: 32
Study 9471828 — intervention group
Group type: COMPARATOR
Intervention: Control group (Corticosteroid infiltration)
Number of subjects: 32
Study 9471828 — intervention group
Group type: COMPARATOR
Intervention: Control group (Low power laser therapy)
Number of subjects: 32
Study 8398330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC), 20 mg/m2 intravenously one day every 6 weeks for four courses, starting before the sixth week after surgery
Number of subjects: 134
Study 8398330 — intervention group
Group type: COMPARATOR
Intervention: Control group with no further treatment after surgery
Number of subjects: 134
Study 8398330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) treatment
Number of subjects: 134
Study 3908435 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir 200 mg five times daily for five days
Number of subjects: 113
Study 3908435 — intervention group
Group type: COMPARATOR
Intervention: matching placebo five times daily for five days
Number of subjects: 113
Study 31937527 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching for 9 months
Number of subjects: 0
Study 31937527 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 30646130 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 2032
Study 30646130 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 2032
Study 30646130 — intervention group
Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 2032
Study 27568492 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ilioinguinal nerve block with additional perineural infiltration of the ilioinguinal, iliohypogastric, genitofemoral nerves (total of 12 mL of 0.5% bupivacaine)
Number of subjects: 92
Study 27568492 — intervention group
Group type: COMPARATOR
Intervention: Control group (Percutaneous ilioinguinal nerve block only)
Number of subjects: 92
Study 24265189 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial amnioinfusion
Number of subjects: 56
Study 24265189 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 56
Study 24265189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 21712736 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (ET)
Number of subjects: 489
Study 21712736 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens + medroxyprogesterone (EPT)
Number of subjects: 489
Study 21712736 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol alone
Number of subjects: 489
Study 21712736 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol + EPT/ET
Number of subjects: 489
Study 21712736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 16105975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 216
Study 16105975 — intervention group
Group type: COMPARATOR
Intervention: Continued conventional chemotherapy
Number of subjects: 216
Study 12269674 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus folate (80 mg iron proteinsuccinylate + 0.370 mg folinic acid daily for 60 days)
Number of subjects: 371
Study 12269674 — intervention group
Group type: COMPARATOR
Intervention: Iron alone (80 mg iron proteinsuccinylate daily for 60 days)
Number of subjects: 371
Study 12269674 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Iron plus folate) in the subgroup with lowest quartile of baseline haemoglobin values
Number of subjects: 371
Study 12269674 — intervention group
Group type: COMPARATOR
Intervention: Iron alone in the subgroup with lowest quartile of baseline haemoglobin values
Number of subjects: 371
Study 9696259 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling/root planing and polishing
Number of subjects: 8
Study 9696259 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 8
Study 7814158 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg orally 15 min before thrombolysis) + Metoprolol (i.v. not later than 1 h, then orally)
Number of subjects: 166
Study 7814158 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg orally 15 min before thrombolysis)
Number of subjects: 166
Study 7814158 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (not later than 1 h)
Number of subjects: 166
Study 7814158 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis only
Number of subjects: 166
Study 2773841 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran injection at 2 months
Number of subjects: 96
Study 2773841 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 96
Study 2773841 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran injection
Number of subjects: 96
Study 319140 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (0.01 mg/kg, maximum 0.25 mg)
Number of subjects: 0
Study 319140 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epinephrine (0.01 mg/kg, maximum 0.25 mg)
Number of subjects: 0
Study 29466285 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Breaks® Physical Activity Solutions (physical activities two times per day for three to five minutes over four months)
Number of subjects: 326
Study 29466285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no use of Brain Breaks® videos during the test period)
Number of subjects: 326
Study 28077835 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart health diary with guided counseling and education for 8 weeks
Number of subjects: 61
Study 25306123 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural audio-visual biofeedback
Number of subjects: 37
Study 25306123 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no biofeedback)
Number of subjects: 37
Study 25306123 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Group (biofeedback)
Number of subjects: 37
Study 22869943 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 60
Study 22869943 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 60
Study 20727552 — intervention group
Group type: EXPERIMENTAL
Intervention: Timer watch assisted urotherapy
Number of subjects: 60
Study 20727552 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy alone
Number of subjects: 60
Study 18280710 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1 to 3 mg/d)
Number of subjects: 50
Study 18280710 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 10 mg/d)
Number of subjects: 50
Study 18280710 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 50
Study 18280710 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50
Study 16897618 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 163
Study 16897618 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 163
Study 12527665 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CCR) programme
Number of subjects: 16
Study 12527665 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study 10642384 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT+CHO (0.36 g tricaprin (C10:0)/kg plus 0.72 g sucrose/kg)
Number of subjects: 7
Study 10642384 — intervention group
Group type: COMPARATOR
Intervention: CHO (0.72 g sucrose/kg)
Number of subjects: 7
Study 8851458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin (1200 mg/d)
Number of subjects: 347
Study 8851458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1500 mg/d)
Number of subjects: 347
Study 8851458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 1510191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (50% oxygen inhalation)
Number of subjects: 25
Study 1510191 — intervention group
Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 25
Study 1510191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 25
Study 6486489 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (2 mg/kg intravenously) after diazepam (15 mg intravenously)
Number of subjects: 6
Study 6486489 — intervention group
Group type: COMPARATOR
Intervention: Placebo after diazepam (15 mg intravenously)
Number of subjects: 6
Study 31240388 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 1000
Study 31240388 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 1000
Study 28437570 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupressure
Number of subjects: 150
Study 28437570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupressure
Number of subjects: 150
Study 28437570 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150